A phase 2a, randomized, double-blind, placebo-controlled,dose-escalation study to evaluate the safety and tolerability of multiple-dose subcutaneous administration of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody,when administered to adults with mild persistent asthma

Trial Profile

A phase 2a, randomized, double-blind, placebo-controlled,dose-escalation study to evaluate the safety and tolerability of multiple-dose subcutaneous administration of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody,when administered to adults with mild persistent asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2014

At a glance

  • Drugs Enokizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 29 Oct 2008 Results were presented at CHEST 2008.
    • 05 Oct 2008 Status changed from suspended to completed, based on information from ClinicalTrials.gov.
    • 25 Aug 2008 Status changed from active, no longer recruiting to suspended, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top